Home › Non-Muscle Invasive Bladder Cancer › NCT07187063
Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer
Recruiting
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * AUA high-risk bladder cancer1 * Received induction BCG or gemcitabine/docetaxel * Negative initial post-induction therapy assessment (negative cytology and cystoscopy +/- biopsy) Exclusion Criteria: * High-risk NMIBC within 3 years * Prior induction intravesical therapy * Variant histology * Concurrent upper tract disease
About the study
The goal of this clinical trial is to use urine tumor DNA (utDNA) as an indicator for non-muscle invasive bladder cancer to identify patients suitable for less frequent cystoscopy surveillance.
What is being tested
- UroAmp Test (Convergent Genomics, Inc.) (diagnostic test)
Sponsor: Lahey Clinic · Participants: 56 · Started: Jan 1, 2025
Contact the study team
- Linda Topjian · Phone: 7817448420
Official record on ClinicalTrials.gov — NCT07187063
Locations in the U.S.
| Massachusetts | Lahey Hospital and Medical Center, Burlington |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.